Syndopa 275 Tablet (Levodopa 250mg / Carbidopa 25mg)

Syndopa 275 Tablet

Syndopa 275 Tablet is an amino acid that is produced and used as a part of the normal biology of human beings, also in some animals and plants. Syndopa 275 Tablet crosses the protective blood–brain barrier as dopamine cannot. Thus, Syndopa 275 Tablet is used to increase the dopamine concentrations in the treatment of Parkinson’s disease and dopamine-responsive dystonia. Besides the central nervous system, Syndopa 275 Tablet can also be converted into dopamine from within the peripheral nervous system.

There are two types of responses seen with the administration of Syndopa 275 Tablet : The short-duration response which is related to the half-life of the drug. The long-duration response depends directly on the accumulation of effects over at least a two week course, during which ΔFosB accumulates in nigrostriatal neurons. When used in the treatment of Parkinson’s disease, this response is seen only in early therapy, as at that stage the inability of the brain to store dopamine is not yet a concern.

Some side effects include hypotension: a result of the dosage being too high, arrhythmias: although this is uncommon, nausea, which can be avoided by taking the drug with food, hair loss, disorientation and, or confusion, an extreme emotional state, particularly anxiety, but also excessive libido.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Neurologist before using this medicine.

Use

Parkinson’s Disease

Related Product

Side Effects

Nausea

Neuroleptic Malignant Syndrome

Panic Attacks

Altered Behaviour

Mood Changes

Altered Sleep

Burning Sensation Of Tongue

Confusion

Convulsions

Dizziness

Drowsiness

Fever

Frequent Dreams

Hallucination

Increased Sweating

Tachycardia

Irregular Heart Rate

Tremor

Vomiting

Worsening Of Tremor

Muscle Stiffness

Work

The active constituent of this medication is structurally an amino acid, a precursor of dopamine. Medication is taken orally crosses the blood-brain barrier and is decarboxylated to dopamine, which is then available to activate dopaminergic receptors. This compensates for the reduced supply of dopamine observed in Parkinson’s disease.